AB-Biotics has finalised a commercial agreement with Abbott Pharmaceuticals (US) to distribute, promote, and market I3.1 probiotic (a strain that targets bloating, gas formation, and pain). Abbott will handle the exclusive promotion of the I3.1 probiotic in Spain, while the Spanish biotechnology firm focuses on R&D and commercialising its personalised medical product pipeline. AB-Biotics has been expanding its system of granting licensing agreements with other companies since 2012.

However, the tie-up with Abbott Pharmaceuticals marks the first licensing agreement for I3.1 probiotic in Europe.